Rebus (RBSH) 10-K 31 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 01, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55331
Entity Registrant Name	REBUS HOLDINGS INC.
Entity Central Index Key	0001421204
Entity Tax Identification Number	20-0438951
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2629 Townsgate Road
Entity Address, Address Line Two	Suite 215
Entity Address, City or Town	Westlake Village
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91361
City Area Code	(818)
Local Phone Number	597-7552
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 3,675,301
Entity Common Stock, Shares Outstanding		32,132,907
Auditor Name	Liggett & Webb, P.A.
Auditor Location	Florida
Auditor Firm ID	287

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 711	$ 404
Prepaid expenses	4	0
Total current assets	715	404
Total assets	715	404
Current liabilities:
Accounts payable	1,801	2,261
Accounts payable – related party	294
Accrued expenses	2,004	1,940
Convertible debentures, net of unamortized discount of $212 and $488	250	1,878
Convertible debentures – related party, net of unamortized discount of $46	154
Derivative liability	1,124	6,828
Total current liabilities	5,627	12,907
Long-term liabilities:
Convertible debentures, net of current	20
Convertible debentures – related party, net of current	90
Total long-term liabilities	110
Total liabilities	5,737	12,907
Commitments and contingencies (Note 8)	0	0
Stockholders’ deficit:
Convertible preferred stock	0	0
Common stock, par value $.0001 per share; 1,000,000,000 shares authorized, 11,769,221 and 2,478,848 shares issued and outstanding, respectively	1	0
Additional paid-in capital	59,254	54,472
Accumulated deficit	(64,277)	(66,975)
Total stockholders’ deficit	(5,022)	(12,503)
Total liabilities and stockholders’ deficit	715	404
Series A Preferred Stock [Member]
Stockholders’ deficit:
Convertible preferred stock	0	0
Series B Preferred Stock [Member]
Stockholders’ deficit:
Convertible preferred stock	0	0
Series C Preferred Stock [Member]
Stockholders’ deficit:
Convertible preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ deficit:
Convertible preferred stock	0	0
Series E Preferred Stock [Member]
Stockholders’ deficit:
Convertible preferred stock	0	0
Series F Preferred Stock [Member]
Stockholders’ deficit:
Convertible preferred stock	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net of unamortized discount, convertible debentures	$ 212	$ 488
Unamortized discount	$ 46	$ 46
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	29,978,846	29,978,846
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	11,769,221	2,478,848
Common stock, shares outstanding	11,769,221	2,478,848
Series A Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	1,854	1,854
Convertible preferred stock, shares issued	134	134
Convertible preferred stock, shares outstanding	134	134
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, shares issued	71	71
Convertible preferred stock, shares outstanding	71	71
Series C Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	300	300
Convertible preferred stock, shares issued	290	290
Convertible preferred stock, shares outstanding	290	290
Series D Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	5,000	5,000
Convertible preferred stock, shares issued	5,000	5,000
Convertible preferred stock, shares outstanding	5,000	5,000
Series E Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	5,000	5,000
Convertible preferred stock, shares issued	5,000	5,000
Convertible preferred stock, shares outstanding	5,000	5,000
Series F Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	8,000	8,000
Convertible preferred stock, shares issued	8,000	8,000
Convertible preferred stock, shares outstanding	8,000	8,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 494	$ 18
License termination cost	0	1,969
General and administrative	528	494
Total operating expenses	1,022	2,481
Loss from operations	(1,022)	(2,481)
Other income (expense):
Gain (loss) on change in fair value of derivative liability	3,687	(3,846)
Gain on conversion of debt	1,116	334
Interest (expense), net	(1,083)	(302)
Income (loss) before provision for income taxes	2,698	(6,295)
Provision for income taxes	0	0
Net income (loss)	2,698	(6,295)
Deemed dividend	0	(64)
Net income (loss) attributable to common shareholders	$ 2,698	$ (6,359)
Net income (loss) per common share, basic	$ 0.35	$ (10.93)
Net income (loss) per common share, diluted	$ (0.07)	$ (10.93)
Weighted average shares outstanding, basic	7,645,188	581,760
Weighted average shares outstanding, diluted	21,132,450	581,760

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019			$ 51,957	$ (60,680)	$ (8,723)
Beginning balance, shares at Dec. 31, 2019	5,495	12,160
Sale of preferred stock			5		5
Sale of preferred stock, shares	5,000
Issuance of preferred stock for license termination
Issuance of preferred stock for license termination, shares	8,000
Issuance of common stock for license termination			267		267
Issuance of common stock for license termination, shares		866,667
Conversion of notes			2,243		2,243
Conversion of notes, shares		1,600,021
Net income				(6,295)	(6,295)
Ending balance, value at Dec. 31, 2020			54,472	(66,975)	(12,503)
Ending balance, shares at Dec. 31, 2020	18,495	2,478,848
Conversion of notes		$ 1	4,446		4,447
Conversion of notes, shares		9,290,364
Director compensation waived			336		336
Issuance of common stock in settlement of options, pursuant to merger
Issuance of common stock in settlement of options, pursuant to merger, shares		9
Net income				2,698	2,698
Ending balance, value at Dec. 31, 2021		$ 1	$ 59,254	$ (64,277)	$ (5,022)
Ending balance, shares at Dec. 31, 2021	18,495	11,769,221

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income (loss)	$ 2,698	$ (6,295)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Common and preferred stock issued for license termination	0	1,944
(Gain) loss on change in fair value of derivative liability	(3,687)	3,846
Gain on conversion of debt	(1,116)	(334)
Amortization of debt discount	828	280
Finance cost	254	20
Changes in operating assets and liabilities:
Prepaid expenses	(4)	0
Accounts payable and accrued expenses	334	165
Cash used in operating activities	(693)	(374)
Cash flows from investing activities:
Cash provided by investing activities	0	0
Cash flows from financing activities:
Proceeds from convertible notes	1,000	750
Proceeds from sale of preferred stock	0	5
Cash provided by financing activities	1,000	755
Net increase in cash	307	381
Cash, beginning of year	404	23
Cash, end of year	$ 711	$ 404

BACKGROUND

BACKGROUND	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND	NOTE 1 – BACKGROUND Rebus Holdings, Inc. (“we”, “us”, “our company”, “our”, “Rebus,” “Rebus Holdings,” or the “Company”) (formerly known as Inspyr Therapeutics, Inc., see below) was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor A2B antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer. The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A antagonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor antagonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain. Pursuant to our recent termination of license with Ridgeway Therapeutics, Inc., a Delaware Corporation (“Ridgeway”), we reacquired the rights to certain intellectual property, discussed above, and are currently focusing on a pipeline of small molecule adenosine receptor modulators. In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development. Our ability to execute the business plan is contingent upon our ability to raise the necessary funds. During March 2020, we sold approximately $ 250,000 500,000 500,000 500,000 Adoption of Agreement and Plan of Merger and Consummation of Reorganization On September 28, 2021 the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to implement a holding company reorganization, which became effective on October 11, 2021 at 5:00 p.m. Eastern Time (the “Effective Time”). The Merger Agreement was entered into by and among Inspyr Therapeutics, Inc., Rebus Holdings, Inc., and Rebus Sub, Inc., a wholly-owned subsidiary of Rebus Holdings which has resulted in Rebus becoming the direct parent company of Inspyr Therapeutics and replacing Inspyr Therapeutics as the public company trading on the OTC Markets (“OTC”) (the “Reorganization”). Further, the Company began trading under the symbol RBSH on November 9, 2021. Pursuant to the Merger Agreement, Rebus Sub merged with Inspyr Therapeutics pursuant to the filing of a certificate of merger with Inspyr Therapeutics surviving as a direct, wholly-owned subsidiary of Rebus Holdings (the “Merger”). At the Effective Time of the Merger: (i) Each outstanding share of Inspyr Therapeutics Common Stock, par value $ 0.0001 (ii) Each outstanding share of Inspyr Series A Convertible Preferred Stock, par value $ 0.0001 0.0001 (iii) Each outstanding share of Inspyr Series B Convertible Preferred Stock, par value $ 0.0001 0.0001 (iv) Each outstanding share of Inspyr Series C Convertible Preferred Stock, par value $ 0.0001 0.0001 (v) Each outstanding share of Inspyr Series D Convertible Preferred Stock, par value $ 0.0001 0.0001 (vi) Each outstanding share of Inspyr Series E Convertible Preferred Stock, par value $ 0.0001 0.0001 (vii) Each outstanding share of Inspyr Series F Convertible Preferred Stock, par value $ 0.0001 0.0001 Accordingly, upon consummation of the Reorganization (and the Reverse Stock Split as defined below), Inspyr stockholders automatically became stockholders of Rebus Holdings, on a one-for-one basis, with the same number and approximate ownership percentage of shares of the same class as they held in Inspyr immediately prior to the Effective Time. The Reorganization was intended to be a tax-free transaction for U.S. federal income tax purposes for Inspyr stockholders. The Reorganization has been conducted pursuant to Section 251(g) of the General Corporation Law of the State of Delaware, which provides for the formation of a holding company without a vote of the stockholders of the constituent corporation. The conversion of stock occurred automatically without an exchange of stock certificates. In addition, at the Effective Time: ● Each outstanding and unexpired option to purchase Inspyr Common Stock automatically converted into share of Rebus Holdings Common Stock; ● Each outstanding warrant to purchase Inspyr Common Stock (“Inspyr Warrant”), whether or not vested, automatically converted into and become a warrant to purchase Rebus Holdings Common Stock (“Rebus Warrant”) and Rebus Holdings assumed each Inspyr Warrant in accordance with the terms of each Inspyr Warrant, and such Rebus Warrant has the same number of shares, the same exercise price (subject to adjustments), the same restrictions on exercise, and any other provisions contained in the Inspyr Warrants; and ● Each outstanding convertible debt instrument of Inspyr Therapeutics, including but not limited to, promissory notes or debentures that are convertible into Inspyr Common Stock (“Inspyr Convertible Notes”) automatically converted into, assumed, and became the convertible debt instruments of Rebus Holdings (“Rebus Convertible Notes”). As a result of the Reorganization, Rebus Holdings became the successor issuer to Inspyr Therapeutics pursuant to Rule 12g-3(a) of the Exchange Act, and as a result, shares of Rebus Holdings Common Stock are deemed registered under Section 12(g) of the Exchange Act as the Common Stock of the successor issuer. Reverse Stock Split On September 1, 2021, the Board of Directors approved a one-for-seventy-five ( 1-for-75 Post Reverse Stock Split and Reorganization Information The Company began trading on post Reverse Stock Split and Reorganization basis on the Pink Sheets of the OTC Markets Group on October 12, 2021. The symbol remained NSPX until November 9, 2021, at which time the Company began trading under the symbol RBSH. The officers and members of the Board of Inspyr became the officers and members of the board of directors of the Rebus Holdings. Pursuant to the Reorganization, Rebus Holdings has, on a consolidated basis, the same assets, businesses, and operations as Inspyr Therapeutics had immediately prior to the Reorganization. Termination of License Agreement On October 5, 2020, the Company entered into an agreement with Ridgeway (“Termination Agreement”) whereby the parties terminated the licensing agreement previously entered into on August 3, 2018 (“Licensing Agreement”), The Company had previously licensed certain technologies related to targeting adenosine receptor antagonists for the treatment of cancer (the “Licensed Assets”). As a result of the Termination Agreement, the Company reacquired full ownership and worldwide rights to all of the Licensed Assets as well as any improvements made thereto. In exchange for entering into the Termination Agreement, the Company issued to Ridgeway: (i) 866,667 8,000 25,000 Pursuant to the Certificate of Designation of the Series F Preferred Stock, each share of Series F Preferred Stock has a stated value of $10.00 per share and is convertible into Common Stock at any time at the election of the holder. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). The Series F Preferred Stock votes on an as if converted to Common Stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Certificate of Designation) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock. Pursuant to the Termination Agreement, in the event that the Company is unable to secure equity financing resulting in aggregate gross proceeds to the Company of at least $ 5,000,000 As a result of the issuance of the Common Shares and Series F Preferred Stock, Ridgeway became the owner of approximately 54.14

MANAGEMENT_S PLANS TO CONTINUE

MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN	12 Months Ended
	Dec. 31, 2021
Managements Plans To Continue As Going Concern
MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN Basis of Presentation The opinion of our independent registered accounting firm on our consolidated financial statements contains explanatory going concern language. We have prepared our consolidated financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses from operations since inception, we have a working capital deficit of $4.9 million and we have an accumulated deficit of $64 million as of December 31, 2021. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions. To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance our product candidates through development. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash balances at December 31, 2021 were approximately $ 711,000 99 500,000 500,000 In the event additional financing is not obtained, we may pursue cost cutting measures as well as explore the sale of assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on our business, results of operations, and financial condition. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our current cash level raises substantial doubt about our ability to continue as a going concern past the third quarter of 2022. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

SUMMARY OF CRITICAL ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Principles of Consolidation The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis & Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated. Reverse Stock Split and Increase in Authorized Shares The one for seventy-five (1-for-75) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. On June 10, 2020, the Company’s Board of Directors approved a one-for-thirty (1-for-30) reverse stock split of the Company’s common stock All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split. Pursuant to a joint written consent of the board of directors and a majority of the voting power of the Company’s stockholders, the Company’s shareholders approved amending and restated the Company’s Certificate of Incorporation to (i) increase the Company’s authorized Common Stock from 150,000,000 1,000,000,000 The Company filed the Amended and Restated Certificate of Incorporation with Delaware’s Secretary of State reflecting the foregoing changes with an effective date and time of November 27, 2020. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates. Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith. We incurred research and development expenses of $ 0.5 0.02 Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did no Restricted Cash Restricted cash consisted of funds held in trust for the Company. The use of these funds was restricted to: (i) the payment of professional fees in connection with bringing the Company’s filings current, and (ii) the payment of vendors associated with the issuance and trading of the Company’s securities, such as transfer agent fees and fees payable to the OTC Markets and FINRA. There were no Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $ 0.7 0.4 Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and have been amortized on the straight line basis over their estimated useful lives of twelve to seventeen years. Income (Loss) per Share Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period. The following potentially dilutive securities have been excluded from the computations of basic weighted average shares outstanding as of December 31, 2021 and 2020, as they would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Year Ended 2021 2020 Shares underlying options outstanding - 16 Shares underlying warrants outstanding 23 53 Shares underlying convertible notes outstanding 35,204,931 6,949,870 Shares underlying convertible preferred stock outstanding 47,172,096 9,995,250 82,377,050 16,945,189 Diluted loss per share for the year ended December 31, 2021 is calculated as follows: Diluted loss per share Year ended December 31, 2021 Net income attributable to common shareholders $ 2,698 Income attributable to convertible instruments (4,928 ) Expense attributable to convertible instruments 829 Diluted loss attributable to common shareholders $ (1,401 ) Basic shares outstanding 7,645,186 Dilutive convertible instruments 13,487,262 Diluted shares outstanding 21,132,448 Diluted loss per share $ (0.07 ) Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations. Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2021 and 2020. The tables below summarize the fair values of our financial liabilities as of December 31, 2021 and 2020 (in thousands): Schedule of fair values of financial liabilities Fair Value at Fair Value Measurement Using 2021 Level 1 Level 2 Level 3 Convertible notes $ 518 — — $ 518 Preferred stock 606 — — 606 Derivative liability $ 1,124 $ — $ — $ 1,124 Fair Value at Fair Value Measurement Using 2020 Level 1 Level 2 Level 3 Convertible notes $ 2,705 — — $ 2,705 Preferred stock 4,123 — — 4,123 Derivative liability $ 6,828 $ — $ — $ 6,828 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) Year ended 2021 2020 Balance at beginning of year $ 6,828 $ 1,785 Additions to derivative instruments 1,354 2,465 Reclassification on conversion (3,371 ) (1,268 ) Loss (gain) on change in fair value of derivative liability (3,687 ) 3,846 Balance at end of year $ 1,124 $ 6,828 Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible. Stock-Based Compensation We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2021 that are of significance or potential significance to the Company. In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION The following table contains additional information for the periods reported (in thousands). Schedule of additional information of cash flow Year Ended 2021 2020 Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability $ 4,447 $ 2,243 Debentures converted to common stock 2,694 1,310 Derivative liability extinguished upon conversion of notes payable 3,371 1,268 Derivative liability issued 1,354 2,465 Accounts payable paid through issuance of debentures 100 100 Accrued director fees forgiven and credited to paid in capital 336 — There was no cash paid for interest and income taxes for the years ended December 31, 2021 and 2020.

INTELLECTUAL PROPERTY

INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTELLECTUAL PROPERTY	NOTE 5 – INTELLECTUAL PROPERTY We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $ 212,000 Intangibles have been fully amortized at December 31, 2021 and 2020.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): Schedule of accrued expenses December 31, 2021 2020 Accrued compensation and benefits $ 1,326 $ 1,326 Accrued research and development 233 233 Accrued other 445 381 Total accrued expenses $ 2,004 $ 1,940

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITY	NOTE 7 – DERIVATIVE LIABILITY We account for equity-linked financial instruments, such as our convertible preferred stock, convertible debentures and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or issuance of a variable number of shares. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant. We have issued convertible debentures and preferred stock which contain variable conversion features, anti-dilution protection and other conversion price adjustment provisions. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that the convertible notes and preferred stock are subject to derivative accounting. The fair value of the conversion feature is classified as a liability in the consolidated financial statements, with the change in fair value during the periods presented recorded in the consolidated statement of losses. During the years ended December 31, 2021 and 2020, we recorded gain of approximately $ 3.7 3.8 Schedule of black scholes valuations of derivatives For the December 31 2021 2020 Expected dividends 0 0 Expected volatility 205 262 343 367 Risk free interest rate 0.06 0.19 0.09 0.095 Expected term 3 6 3 12 As of December 31, 2021 and 2020, the derivative liability recognized in the financial statements was approximately $ 1.1 6.8

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Operating Leases The Company currently does not have any ongoing leases for office space. It has availability to office space on an as needed basis. Its employees work on a remote basis. There was no Legal Matters The Company is subject at times to legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. COVID-19 Uncertainty On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The extent of the public-health impact of the outbreak is currently unknown and rapidly evolving, and the related health crisis could adversely affect the global economy, resulting in an economic downturn. Any disruption of the Company’s facilities or those of our suppliers could likely adversely impact the Company’s operations. At this time, there is significant uncertainty relating to the potential effect of the novel coronavirus on our business.

CAPITAL STOCK AND STOCKHOLDERS_

CAPITAL STOCK AND STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
CAPITAL STOCK AND STOCKHOLDERS’ EQUITY	NOTE 9 – CAPITAL STOCK AND STOCKHOLDERS’ EQUITY Preferred Stock As of December 31, 2021, there were outstanding 134 71 290 5,000 5,000 8,000 Series F Preferred Stock On October 6, 2020, the Company filed a certificate of designation of Series F Preferred Stock (“Series F COD”) with the Secretary of State of the State of Delaware that contains the rights, preferences, and privileges of the Series F Preferred Stock. Pursuant to the Series F COD, each share of Series F Preferred Stock has a stated value of $ 10.00 8,000 Series E Preferred Stock On May 2, 2020, we sold 5,000 1.00 5,000 1.00 22.50 As provided for in the Series E COD, with respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2022 only, each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes. Series D Preferred Stock During December 2018, we designated 5,000 0.0001 1.00 5,000 5,000 281.25 On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series D Preferred Stock shall vote together with the holders of Common Stock as a single class. Series C Preferred Stock In March and April 2017, we issued 290.43148 1,000 1,125.00 562.50 90.43418 Series B Preferred Stock In December 2016, we issued 1,000 1,000 0.75 Series A Preferred Stock In December 2015, we issued 1,853 1,000 29,812.50 As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2021, (ii) our Series B Preferred Stock has been reduced to $0.75 per share at December 31, 2021, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2021, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2021. As a result of the reductions of the conversion prices of our preferred stock, we have recorded a deemed dividend of approximately $ 64,000 Common Stock Increase in Authorized Shares Pursuant to a joint written consent of the board of directors and a majority of the voting power of the Company’s stockholders, the Company’s shareholders approved amending and restated the Company’s Certificate of Incorporation to (i) increase the Company’s authorized Common Stock from 150,000,000 1,000,000,000 The Company filed the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State reflecting the foregoing changes with an effective date and time of November 27, 2020. Reverse Stock Splits On September 1, 2021, the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split. On June 10, 2020, the Company’s Board of Directors approved the 2020 Reverse Stock Split with a ratio of the one-for-thirty (1-for-30). Pursuant to the 2020 Reverse Stock Split, the Company filed an amended and restated certificate of incorporation with the Secretary of State of Delaware to effect the 2020 Reverse Stock Split effective as of 5:00 p.m. Eastern Time on June 26, 2020. Accordingly, at the 2020 Effective Time, each of the Company’s common stock shareholders received one new share of common stock for every thirty shares such shareholder held immediately prior to the 2020 Effective Time. The 2020 Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the 2020 Reverse Stock Split ratio. All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split.. Common Stock Activity During the year ended December 31, 2021, we issued a total of 9,290,364 4,447,246 2,693,596 1,116,424 During the year ended December 31, 2021, we issued a total of 9 shares of common stock in settlement of outstanding options, pursuant to the merger discussed in Note 1. During the three months ended March 31, 2021, we entered into settlement and release agreements with two of our independent directors for the settlement of past due director fees and the mutual release of all claims. Pursuant to the agreements, the directors agreed to waive an aggregate of $ 435,667 the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021 In October 2020, we issued 866,667 266,500 During the year ended December 31, 2020, we issued a total of 1,600,021 2,243,628 1,310,068 334,206

STOCK OPTIONS

STOCK OPTIONS	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 10 – STOCK OPTIONS Deferred Compensation Plan In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards. Company Compensation Plans The Company’s 2007 Equity Compensation Plan (2007 Plan), 2009 Executive Compensation Plan (2009 Plan), 2017 Equity Compensation Plan (2017 Plan), and the Inducement Award Stock Option Plan (Inducement Plan) (together, the Plans) provided for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of the Company and its stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans were administered by a committee of non-employee directors (the Committee). The Committee determined: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award. Termination of Compensation Plans Our 2007 Equity Compensation Plan, 2009 Executive Compensation Plan, Inducement Award Stock Option Plan and 2017 Equity Compensation Plan have all expired or been terminated by the Board as of December 31, 2021. The following table summarizes stock option activity for the years ended December 31, 2021 and 2020: Schedule of stock option activity Number of Weighted- average Weighted- average Outstanding at December 31, 2019 28 $ 855,753 Granted — $ — Forfeited (12 ) $ 1,522,968 Outstanding at December 31, 2020 16 $ 355,342 2.4 Granted — $ — Settled with shares pursuant to merger (9 ) $ 477,238 Forfeited (7 ) $ 198,619 Outstanding at December 31, 2021 — $ — — Exercisable at December 31, 2021 — $ — — No options were issued or exercised during the years ended December 31, 2021 and 2020. The options had no intrinsic value at December 31, 2021.

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2021
Warrants
WARRANTS	NOTE 11 – WARRANTS Transactions involving our warrants are summarized as follows: Schedule of transactions involving of warrants Number of Weighted- average Weighted- average Outstanding at December 31, 2019 83 $ 225,842 Granted — $ — Forfeited (30 ) $ 615,938 Outstanding at December 31, 2020 53 $ 5,033 1.0 Granted — $ — Forfeited (30 ) $ 22 Outstanding at December 31, 2021 23 $ 11,568 0.3 Exercisable at December 31, 2021 23 $ 11,568 0.3 No warrants were issued or exercised during the years ended December 31, 2021 and 2020. The warrants had no intrinsic value at December 31, 2021. As a result of recent equity financings and conversions of debentures, the exercise prices of the warrants issued in conjunction with our Series B preferred stock have been reduced to $ 22.50 562.50 1,125.00 The following table summarizes outstanding common stock purchase warrants as of December 31, 2021: Schedule of outstanding common stock purchase warrants Number of Weighted- average Expiration Issued to consultants 1 $ 244,688 August 2023 Issued pursuant to 2017 financings 22 $ 972 March 2022 through April 2022 23

CONVERTIBLE DEBENTURES AND NOTE

CONVERTIBLE DEBENTURES AND NOTES	12 Months Ended
	Dec. 31, 2021
Convertible Debentures And Notes
CONVERTIBLE DEBENTURES AND NOTES	NOTE 12 – CONVERTIBLE DEBENTURES AND NOTES Extension of Outstanding Debentures until June 30, 2021 Effective March 6, 2020, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. (collectively, the “Sabby Entities”) waived certain events of default under debentures and notes issued in our December 2018 note offering, July 2018 debenture offering and September 2017 debenture offering (collectively, the “Debenture Offerings”) and extended the maturity date of such debentures until July 16, 2020. Effective July 16, 2020, the maturity dates of all of the debentures was extended to December 31, 2020. Effective December 31, 2020, the maturity dates of all debentures that matured during 2020 were extended to June 30, 2021. Conversion Price Adjustment Agreement On November 25, 2020, the Company entered into a conversion price adjustment agreement (the “Adjustment Agreement”) with the Sabby Entities. Pursuant to the Adjustment Agreement, approximately $ 2.4 24.75 85 June 2021 Debentures On June 18, 2021, the Company sold an aggregate of $ 600,000 500,000 100,000 June 18, 2022 9.99 have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein. The June Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the June Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the June Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the June Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the June Debentures. During the year ended December 31, 2021, $ 38,028 561,972 We recorded an initial derivative liability of $ 644,457 600,000 44,457 324,561 17,689 257,750 January 2021 Debenture On January 12, 2021, we sold a $ 500,000 500,000 January 12, 2022 9.99 has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein. The January Debenture also contains provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investor also has the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the January Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the January Debenture is no longer outstanding. Additionally, the Company has the option to redeem some or all of the January Debenture for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the January Debenture. The January Debentures were fully converted to Common Stock during the year ended December 31, 2021. We recorded an initial derivative liability of $ 709,835 500,000 209,835 327,450 172,550 October 2020 Debentures On October 23, 2020, the Company sold an aggregate of $ 600,000 500,000 100,000 The October Debentures (i) are non-interest bearing, (ii) have a maturity date of October 23, 2021 9.99 have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The October Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the October Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the October Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the October Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the October Debentures. Without the approval of the October Debenture holders holding at least 67% of the then outstanding principal amount of the October Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any holder, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. During the year ended December 31, 2021, $ 500,000 100,000 We had recorded debt discount of $ 600,000 176,389 112,500 311,111 619,627 600,000 19,627 March 2020 Debentures On March 6, 2020, the Company sold an aggregate of $ 250,000 July 16, 2020 9.99 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021. The March Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the March Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the March Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the March Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the March Debentures. Furthermore, without the approval of the debenture holders holding at least 67% of the then outstanding principal amount of the March Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any investor, (ii) repay or repurchase or acquire shares of its common stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The March Debentures were fully converted to Common Stock during the year ended December 31, 2021. We recorded debt discount of $ 167,080 November 2019 Debentures Sabby Volatility Warrant Master Fund, Ltd. has paid certain of our accounts payable in the amount of $ 26,235 26,235 The debentures were fully converted to Common Stock during the year ended December 31, 2021. October 2019 Debentures Effective September 30 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our Debenture Offerings and extended the maturity date of such debentures until March 31, 2020 in exchange for the issuance of $ 96,000 The debentures were fully converted to Common Stock during the year ended December 31, 2021. July 2019 Debentures On July 16, 2019, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we issued an aggregate of $ 154,000 154,000 The July 2019 Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the investor at any time, subject to a beneficial ownership limitation of 4.99 9.99 by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. Furthermore, without the approval of the investors holding at least 67% of the then outstanding principal amount of the July 2019 Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also obligated under the Securities Purchase Agreement to pay investors, as partial liquidated damages, a fee of 2.0% of each investor’s initial principal amount of such investor’s July 2019 Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures. The July 2019 Debentures were fully converted to Common Stock during the year ended December 31, 2021. December 2018 Notes On December 13, 2018 we issued an aggregate of $ 25,000 25,000 June 30, 2019 10 75 The Notes were fully converted to Common Stock during the year ended December 31, 2021. July 2018 Debentures On July 3, 2018, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we sold an aggregate of $ 515,000 500,000 15,000 515,000 The July 2018 Debentures were fully converted to common stock during the year ended December 31, 2021. September 2017 Debentures On September 12, 2017, we entered into an exchange agreement (“Exchange Agreement”) with certain holders of our Series A Preferred Stock and Series B Preferred Stock. Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $ 2.5 1,614 1.6 890 0.9 On September 12, 2017, we sold an aggregate of $ 320,000 250,000 70,000 The September 2017 Debentures have substantially the same terms as the July 2019 Debentures. The maturity date of the September 2017 Debentures has been extended to December 31, 2022. During the years ended December 31, 2021 and 2020, $ 589,334 1,310,068 110,072 As a result of a buy-in failure to deliver certain shares pursuant to a debenture conversion, the Company incurred penalties of $ 24,551

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 13 — RELATED PARTY TRANSACTIONS In September of 2021, we began paying $ 10,000 84,224 40,000 54,141 294,005 290,000

LICENSE TERMINATION COST

LICENSE TERMINATION COST	12 Months Ended
	Dec. 31, 2021
License Termination Cost
LICENSE TERMINATION COST	NOTE 14 — LICENSE TERMINATION COST As described in Note 1, on October 5, 2020, we entered into an agreement with Ridgeway Therapeutics, Inc. whereby the parties terminated the Licensing Agreement previously entered into on August 3, 2018. In exchange for entering into the Termination Agreement, the Company issued to Ridgeway 866,667 shares of common stock and 8,000 shares of Series F 0% Convertible Preferred Stock. Additionally, the Company paid approximately $25,000 of Ridgeway’s expenses and costs. We valued the 866,667 266,500 1,677,901

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 15 — INCOME TAXES The Company had, subject to limitation, $ 43 39.9 expire at various dates through 2037. 485,000 expire from 2028 through 2041. 306,000 226,000 Schedule of deferred tax assets and liabilities 2021 2020 Deferred tax assets: Net operating loss carryover $ 9,343 $ 9,064 Stock-based compensation 1,920 1,920 Accrued compensation 334 334 Other 30 30 Tax credits 485 458 Total deferred tax assets 12,112 11,806 Less: valuation allowance (12,112 ) (11,806 ) Net deferred tax assets $ — $ — The above NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL carryforward that can be utilized to offset future taxable income. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis. If a change in ownership were to have occurred, NOL carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate. The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2021 and 2020 (computed by applying the U.S. Federal Corporate tax rate of 21% to income before taxes) are as follows: Schedule of actual tax benefit differs from the expected tax benefit 2021 2020 Statutory federal income tax rate ( 21.0 )% ( 21.0 )% State income taxes, net of federal benefits ( 7.0 )% ( 7.0 )% Non-deductible items 38.3 % 24.4 % Valuation allowance ( 10.3 )% 3.6 % Effective income tax rate — % — % The Company’s tax returns for the previous three years remain open for audit by the respective tax jurisdictions.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 – SUBSEQUENT EVENTS Subsequent to the year ending December 31, 2021, debenture holders converted $ 461,972 20,363,686

SUMMARY OF CRITICAL ACCOUNTIN_2

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis & Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated.
Reverse Stock Split and Increase in Authorized Shares	Reverse Stock Split and Increase in Authorized Shares The one for seventy-five (1-for-75) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. On June 10, 2020, the Company’s Board of Directors approved a one-for-thirty (1-for-30) reverse stock split of the Company’s common stock All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split. Pursuant to a joint written consent of the board of directors and a majority of the voting power of the Company’s stockholders, the Company’s shareholders approved amending and restated the Company’s Certificate of Incorporation to (i) increase the Company’s authorized Common Stock from 150,000,000 1,000,000,000 The Company filed the Amended and Restated Certificate of Incorporation with Delaware’s Secretary of State reflecting the foregoing changes with an effective date and time of November 27, 2020.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith. We incurred research and development expenses of $ 0.5 0.02
Cash Equivalents	Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did no
Restricted Cash	Restricted Cash Restricted cash consisted of funds held in trust for the Company. The use of these funds was restricted to: (i) the payment of professional fees in connection with bringing the Company’s filings current, and (ii) the payment of vendors associated with the issuance and trading of the Company’s securities, such as transfer agent fees and fees payable to the OTC Markets and FINRA. There were no
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $ 0.7 0.4
Intangible Assets	Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and have been amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.
Income (Loss) per Share	Income (Loss) per Share Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period. The following potentially dilutive securities have been excluded from the computations of basic weighted average shares outstanding as of December 31, 2021 and 2020, as they would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Year Ended 2021 2020 Shares underlying options outstanding - 16 Shares underlying warrants outstanding 23 53 Shares underlying convertible notes outstanding 35,204,931 6,949,870 Shares underlying convertible preferred stock outstanding 47,172,096 9,995,250 82,377,050 16,945,189 Diluted loss per share for the year ended December 31, 2021 is calculated as follows: Diluted loss per share Year ended December 31, 2021 Net income attributable to common shareholders $ 2,698 Income attributable to convertible instruments (4,928 ) Expense attributable to convertible instruments 829 Diluted loss attributable to common shareholders $ (1,401 ) Basic shares outstanding 7,645,186 Dilutive convertible instruments 13,487,262 Diluted shares outstanding 21,132,448 Diluted loss per share $ (0.07 )
Derivative Liability	Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Fair Value Measurements	Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2021 and 2020. The tables below summarize the fair values of our financial liabilities as of December 31, 2021 and 2020 (in thousands): Schedule of fair values of financial liabilities Fair Value at Fair Value Measurement Using 2021 Level 1 Level 2 Level 3 Convertible notes $ 518 — — $ 518 Preferred stock 606 — — 606 Derivative liability $ 1,124 $ — $ — $ 1,124 Fair Value at Fair Value Measurement Using 2020 Level 1 Level 2 Level 3 Convertible notes $ 2,705 — — $ 2,705 Preferred stock 4,123 — — 4,123 Derivative liability $ 6,828 $ — $ — $ 6,828 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) Year ended 2021 2020 Balance at beginning of year $ 6,828 $ 1,785 Additions to derivative instruments 1,354 2,465 Reclassification on conversion (3,371 ) (1,268 ) Loss (gain) on change in fair value of derivative liability (3,687 ) 3,846 Balance at end of year $ 1,124 $ 6,828
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.
Stock-Based Compensation	Stock-Based Compensation We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2021 that are of significance or potential significance to the Company. In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

SUMMARY OF CRITICAL ACCOUNTIN_3

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Year Ended 2021 2020 Shares underlying options outstanding - 16 Shares underlying warrants outstanding 23 53 Shares underlying convertible notes outstanding 35,204,931 6,949,870 Shares underlying convertible preferred stock outstanding 47,172,096 9,995,250 82,377,050 16,945,189
Diluted loss per share	Diluted loss per share Year ended December 31, 2021 Net income attributable to common shareholders $ 2,698 Income attributable to convertible instruments (4,928 ) Expense attributable to convertible instruments 829 Diluted loss attributable to common shareholders $ (1,401 ) Basic shares outstanding 7,645,186 Dilutive convertible instruments 13,487,262 Diluted shares outstanding 21,132,448 Diluted loss per share $ (0.07 )
Schedule of fair values of financial liabilities	Schedule of fair values of financial liabilities Fair Value at Fair Value Measurement Using 2021 Level 1 Level 2 Level 3 Convertible notes $ 518 — — $ 518 Preferred stock 606 — — 606 Derivative liability $ 1,124 $ — $ — $ 1,124 Fair Value at Fair Value Measurement Using 2020 Level 1 Level 2 Level 3 Convertible notes $ 2,705 — — $ 2,705 Preferred stock 4,123 — — 4,123 Derivative liability $ 6,828 $ — $ — $ 6,828
Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3)	Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) Year ended 2021 2020 Balance at beginning of year $ 6,828 $ 1,785 Additions to derivative instruments 1,354 2,465 Reclassification on conversion (3,371 ) (1,268 ) Loss (gain) on change in fair value of derivative liability (3,687 ) 3,846 Balance at end of year $ 1,124 $ 6,828

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of additional information of cash flow	Schedule of additional information of cash flow Year Ended 2021 2020 Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability $ 4,447 $ 2,243 Debentures converted to common stock 2,694 1,310 Derivative liability extinguished upon conversion of notes payable 3,371 1,268 Derivative liability issued 1,354 2,465 Accounts payable paid through issuance of debentures 100 100 Accrued director fees forgiven and credited to paid in capital 336 —

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of accrued expenses	Schedule of accrued expenses December 31, 2021 2020 Accrued compensation and benefits $ 1,326 $ 1,326 Accrued research and development 233 233 Accrued other 445 381 Total accrued expenses $ 2,004 $ 1,940

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of black scholes valuations of derivatives	Schedule of black scholes valuations of derivatives For the December 31 2021 2020 Expected dividends 0 0 Expected volatility 205 262 343 367 Risk free interest rate 0.06 0.19 0.09 0.095 Expected term 3 6 3 12

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	Schedule of stock option activity Number of Weighted- average Weighted- average Outstanding at December 31, 2019 28 $ 855,753 Granted — $ — Forfeited (12 ) $ 1,522,968 Outstanding at December 31, 2020 16 $ 355,342 2.4 Granted — $ — Settled with shares pursuant to merger (9 ) $ 477,238 Forfeited (7 ) $ 198,619 Outstanding at December 31, 2021 — $ — — Exercisable at December 31, 2021 — $ — —

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2021
Warrants
Schedule of transactions involving of warrants	Schedule of transactions involving of warrants Number of Weighted- average Weighted- average Outstanding at December 31, 2019 83 $ 225,842 Granted — $ — Forfeited (30 ) $ 615,938 Outstanding at December 31, 2020 53 $ 5,033 1.0 Granted — $ — Forfeited (30 ) $ 22 Outstanding at December 31, 2021 23 $ 11,568 0.3 Exercisable at December 31, 2021 23 $ 11,568 0.3
Schedule of outstanding common stock purchase warrants	Schedule of outstanding common stock purchase warrants Number of Weighted- average Expiration Issued to consultants 1 $ 244,688 August 2023 Issued pursuant to 2017 financings 22 $ 972 March 2022 through April 2022 23

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	Schedule of deferred tax assets and liabilities 2021 2020 Deferred tax assets: Net operating loss carryover $ 9,343 $ 9,064 Stock-based compensation 1,920 1,920 Accrued compensation 334 334 Other 30 30 Tax credits 485 458 Total deferred tax assets 12,112 11,806 Less: valuation allowance (12,112 ) (11,806 ) Net deferred tax assets $ — $ —
Schedule of actual tax benefit differs from the expected tax benefit	Schedule of actual tax benefit differs from the expected tax benefit 2021 2020 Statutory federal income tax rate ( 21.0 )% ( 21.0 )% State income taxes, net of federal benefits ( 7.0 )% ( 7.0 )% Non-deductible items 38.3 % 24.4 % Valuation allowance ( 10.3 )% 3.6 % Effective income tax rate — % — %

BACKGROUND (Details Narrative)

BACKGROUND (Details Narrative) - USD ($)	Jun. 10, 2020	Sep. 17, 2019	Dec. 31, 2021	Jun. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Debt securities sold								$ 250,000
Convertible preferred stock, par value			$ 0.0001			$ 0.0001
Reverse stock split	the Company’s Board of Directors approved a one-for-thirty (1-for-30) reverse stock split of the Company’s common stock	the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split.	1-for-75
Common stock shares issued			866,667
Payment for expenses and costs			$ 25,000
Proceeds from equity financing			$ 5,000,000
Percentage of issued and outstanding shares of common stock			54.14%
Inspyr Common Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			$ 0.0001
Inspyr Series A Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series A Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series B Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series B Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series C Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series C Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series D Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series D Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series E Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series E Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Inspyr Series F Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			0.0001
Rebus Series F Stock [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock, par value			$ 0.0001
Series F Preferred Stocks [Member]
Finite-Lived Intangible Assets [Line Items]
Convertible preferred stock			8,000
Cash [Member]
Finite-Lived Intangible Assets [Line Items]
Debt securities sold				$ 500,000	$ 500,000		$ 500,000
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Description of cancellation of a license agreement			In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.

MANAGEMENT_S PLANS TO CONTINU_2

MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021	Jan. 31, 2021
Managements Plans To Continue As Going Concern
Cash and cash equivalents and restricted cash balances	$ 711,000
Percentage of total assets	99.00%
Amount raised		$ 500,000	$ 500,000

SUMMARY OF CRITICAL ACCOUNTIN_4

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Shares underlying, outstanding	82,377,050	16,945,189
Convertible Preferred Stock [Member]
Shares underlying, outstanding	47,172,096	9,995,250
Convertible Debt [Member]
Shares underlying, outstanding	35,204,931	6,949,870
Warrant [Member]
Shares underlying, outstanding	23	53
Share-based Payment Arrangement, Option [Member]
Shares underlying, outstanding	0	16

SUMMARY OF CRITICAL ACCOUNTIN_5

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Net income attributable to common shareholders	$ 2,698	$ (6,359)
Income attributable to convertible instruments	(4,928)
Expense attributable to convertible instruments	829
Diluted loss attributable to common shareholders	$ (1,401)
Basic shares outstanding	7,645,186
Dilutive convertible instruments	13,487,262
Diluted shares outstanding	21,132,448
Diluted loss per share	$ (0.07)

SUMMARY OF CRITICAL ACCOUNTIN_6

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Convertible notes	$ 518	$ 2,705
Preferred stock	606	4,123
Derivative liability	1,124	6,828
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Convertible notes	0	0
Preferred stock	0	0
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Convertible notes	0	0
Preferred stock	0	0
Derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Convertible notes	518	2,705
Preferred stock	606	4,123
Derivative liability	$ 1,124	$ 6,828

SUMMARY OF CRITICAL ACCOUNTIN_7

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Balance at beginning of year	$ 6,828	$ 1,785
Additions to derivative instruments	1,354	2,465
Reclassification on conversion	(3,371)	(1,268)
Loss (gain) on change in fair value of derivative liability	(3,687)	3,846
Balance at end of year	$ 1,124	$ 6,828

SUMMARY OF CRITICAL ACCOUNTIN_8

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative) - USD ($)	Jun. 10, 2020	Sep. 17, 2019	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Reverse stock split, description	the Company’s Board of Directors approved a one-for-thirty (1-for-30) reverse stock split of the Company’s common stock	the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split.	1-for-75
Common stock shares authorized			150,000,000
Common stock shares authorized				1,000,000,000
Research and development			$ 500,000	$ 20,000
Cash equivalents			0	0
Restricted Cash			0	0
Cash			$ 700,000	$ 400,000

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Non-cash financial activities:
Common stock issued on conversion of notes payable and derivative liability	$ 4,447	$ 2,243
Debentures converted to common stock	2,694	1,310
Derivative liability extinguished upon conversion of notes payable	3,371	1,268
Derivative liability issued	1,354	2,465
Accounts payable paid through issuance of debentures	100	100
Accrued director fees forgiven and credited to paid in capital	$ 336	$ 0

INTELLECTUAL PROPERTY (Details

INTELLECTUAL PROPERTY (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Payments in cash and common stock	$ 212,000

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued compensation and benefits	$ 1,326	$ 1,326
Accrued research and development	233	233
Accrued other	445	381
Total accrued expenses	$ 2,004	$ 1,940

DERIVATIVE LIABILITY (Details)

DERIVATIVE LIABILITY (Details)	Dec. 31, 2021	Dec. 31, 2020
Measurement Input, Expected Dividend Rate [Member]
Derivative [Line Items]
Derivative liability measurement input	0.00%	0.00%
Measurement Input, Price Volatility [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability measurement input	205.00%	343.00%
Measurement Input, Price Volatility [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability measurement input	262.00%	367.00%
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability measurement input	0.06%	0.09%
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability measurement input	0.19%	0.095%
Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability term	3 months	3 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability term	6 months	12 months

DERIVATIVE LIABILITY (Details N

DERIVATIVE LIABILITY (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gain and loss on change in fair value of the derivative liability	$ 3,700	$ 3,800
Derivative Liability	$ 1,100	$ 6,800

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Rental expenses	$ 0	$ 0

CAPITAL STOCK AND STOCKHOLDER_2

CAPITAL STOCK AND STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Oct. 06, 2020	Jun. 10, 2020	May 02, 2020	Sep. 17, 2019	Oct. 31, 2020	Dec. 31, 2018	Apr. 30, 2017	Dec. 31, 2015	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2016
Class of Stock [Line Items]
Preferred stock, shares outstanding										0	0
Stock issued during period, shares										866,667
Conversion price per share										$ 22.50
Preferred stock, shares authorized										29,978,846	29,978,846
Preferred stock, stated value										$ 0.0001	$ 0.0001
Preferred stock shares issued										0	0
Conversion price, description										As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2021, (ii) our Series B Preferred Stock has been reduced to $0.75 per share at December 31, 2021, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2021, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2021.
Common stock increase in authorized shares										150,000,000
Common stock decrease in authorized shares										1,000,000,000
Reverse stock split, description		the Company’s Board of Directors approved a one-for-thirty (1-for-30) reverse stock split of the Company’s common stock		the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split.						1-for-75
Common stock shares issued activity										9,290,364	1,600,021
Common stock valued activity										$ 4,447,246	$ 2,243,628
Principal amount activity convertible										2,693,596	1,310,068
Gain of conversion of debt activity										$ 1,116,424	$ 334,206
Directors fees waived									$ 435,667
Directors fees waived description									the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021
Common stock shares issued					866,667
Fair value amount					$ 266,500
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding										134	134
Conversion price per share								$ 29,812.50
Preferred stock, shares authorized										1,854	1,854
Preferred stock, stated value								$ 1,000		$ 0.0001	$ 0.0001
Preferred stock shares issued								1,853		134	134
Deemed dividend								$ 64,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding										71	71
Conversion price per share												$ 0.75
Preferred stock, shares authorized										1,000	1,000
Preferred stock, stated value										$ 0.0001	$ 0.0001	$ 1,000
Preferred stock shares issued										71	71	1,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding										290	290
Conversion price per share							$ 1,125
Preferred stock, shares authorized										300	300
Preferred stock, stated value							$ 1,000			$ 0.0001	$ 0.0001
Preferred stock shares issued							290.43148			290	290
Preferred stock shares valued							$ 562.50
Beneficial ownwership interests							90.43418
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding										5,000	5,000
Conversion price per share						$ 281.25
Preferred stock, shares authorized						5,000				5,000	5,000
Preferred stock, par value						$ 0.0001
Preferred stock, stated value						$ 1				$ 0.0001	$ 0.0001
Preferred stock shares issued						5,000				5,000	5,000
Proceeds of preferred stock						$ 5,000
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding										5,000	5,000
Preferred stock, voting right										each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes.
Preferred stock, shares authorized										5,000	5,000
Preferred stock, stated value										$ 0.0001	$ 0.0001
Preferred stock shares issued										5,000	5,000
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding										8,000	8,000
Preferred stock, stated value	$ 10
Preferred stock, shares authorized										8,000	8,000
Preferred stock, stated value										$ 0.0001	$ 0.0001
Preferred stock shares issued										8,000	8,000
Series F Preferred Stock [Member] | Ridgeway Therapeutics, Inc [Member]
Class of Stock [Line Items]
Stock issued during period, shares	8,000
Series E 0% Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, stated value			$ 1
Sale of stock, shares			5,000
Sale of stock value			$ 5,000
Sale of stock, price per share			$ 1

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - Equity Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Offsetting Assets [Line Items]
Outstanding at beginning	16	28
Outstanding at beginning	$ 355,342	$ 855,753
Granted	0	0
Granted	$ 0	$ 0
Forfeited	(7)	(12)
Forfeited	$ 198,619	$ 1,522,968
Outstanding at ending	0	16
Outstanding at ending	$ 0	$ 355,342
Outstanding at ending	2 years 4 months 24 days
Settled with shares pursuant to merger	(9)
Settled with shares pursuant to merger	$ 477,238
Exercisable at ending	0
Exercisable at ending	$ 0

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding at beginning	53	83
Outstanding at beginning	$ 5,033	$ 225,842
Granted	0	0
Granted	$ 0	$ 0
Forfeited	(30)	(30)
Forfeited	$ 22	$ 615,938
Outstanding at ending	23	53
Outstanding at ending	$ 11,568	$ 5,033
Outstanding at ending	3 months 18 days	1 year
Exercisable at ending	23
Exercisable at ending	$ 11,568
Exercisable at ending	3 months 18 days

WARRANTS (Details 1)

WARRANTS (Details 1) - Warrant [Member]	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Number of shares	23
Financings 2017 [Member]
Number of shares	22
Weighted Average Exercise price | $ / shares	$ 972
Expiration date ending	March 2022 through April 2022
Consultant [Member]
Number of shares	1
Weighted Average Exercise price | $ / shares	$ 244,688
Expiration date ending	August 2023

WARRANTS (Details Narrative)

WARRANTS (Details Narrative)	Dec. 31, 2021$ / shares
Series B Preferred Stock [Member]
Exercise price of warrants	$ 22.50
Series C Preferred Stock [Member] | Minimum [Member]
Exercise price of warrants	562.50
Series C Preferred Stock [Member] | Maximum [Member]
Exercise price of warrants	$ 1,125

CONVERTIBLE DEBENTURES AND NO_2

CONVERTIBLE DEBENTURES AND NOTES (Details Narrative) - USD ($)

Jan. 12, 2021

Mar. 06, 2020

Dec. 13, 2018

Jul. 03, 2018

Sep. 12, 2017

Sep. 12, 2017

Jun. 18, 2021

Nov. 25, 2020

Oct. 23, 2020

Jul. 16, 2019

Dec. 31, 2021

Dec. 31, 2020

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Remaining debt outstanding

$ 518,000

$ 2,705,000

Conversion price, description

As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2021, (ii) our Series B Preferred Stock has been reduced to $0.75 per share at December 31, 2021, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2021, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2021.

Derivative liability

$ 1,100,000

6,800,000

Unamortized of debt discount

212,000

488,000

Debt conversion amount

2,694,000

1,310,000

Finance cost

254,000

20,000

Stated value of the preferred shares

0

0

Incurred penalities

24,551

June 2021 Debenture [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Principal amount

$ 600,000

Cash received

500,000

Cancellation amount

$ 100,000

Maturity date

Jun. 18, 2022

Beneficial ownership limitation percentage

9.99%

Conversion price, description

have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.

Converted debentures

38,028

Debentures remaining amount

561,972,000

Derivative liability

$ 644,457

Debt discount

600,000

Interest Expense, Debt

$ 44,457

Debt discount

324,561

Amortization of debt charged off

17,689

Unamortized of debt discount

257,750

January 2021 Debenture [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Principal amount

$ 500,000

Cash received

$ 500,000

Maturity date

Jan. 12, 2022

Beneficial ownership limitation percentage

9.99%

Conversion price, description

has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.

Derivative liability

$ 709,835

Debt discount

500,000

Interest Expense, Debt

$ 209,835

Debt discount

327,450

Gain on charged off conversion of debentures

172,550

October 2020 Debentures [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Principal amount

$ 600,000

Cash received

500,000

Cancellation amount

$ 100,000

Maturity date

Oct. 23, 2021

Beneficial ownership limitation percentage

9.99%

Conversion price, description

have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.

Debt discount

$ 600,000

600,000

Debt discount

176,389

Gain on charged off conversion of debentures

311,111

Debt conversion amount

500,000

Debt conversion amount remains outstanding

100,000

Interest expense debt

112,500

Fair value intial derivative liability

619,627

Interest expense

19,627

March 2020 Debentures [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Principal amount

$ 250,000

Maturity date

Jul. 16, 2020

Beneficial ownership limitation percentage

9.99%

Conversion price, description

Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021.

Debt discount

167,080

November 2019 Debentures [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Debt conversion amount

26,235

Accounts payable

26,235

October 2019 Debentures [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Debt conversion amount

$ 96,000

July 2019 Debenture [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Conversion price, description

by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.

July 2019 Debenture [Member] | Minimum [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Beneficial ownership limitation percentage

4.99%

July 2019 Debenture [Member] | Maximum [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Beneficial ownership limitation percentage

9.99%

December 2018 Debentures [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Principal amount

$ 25,000

$ 515,000

Cash received

$ 25,000,000

Maturity date

Jun. 30, 2019

Interest rate

10.00%

Trading price

75.00%

Exchange Agreement [Member] | Investors [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Remaining debt outstanding

$ 2,500,000

$ 2,500,000

Series A Convertible Preferred Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Stated value of the preferred shares

1,614

Stated value of the preferred shares

$ 1,600,000

1,600,000

Series B Convertible Preferred Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Stated value of the preferred shares

$ 900,000

$ 900,000

Preferred shares exchanged

890

890

Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Remaining debt outstanding

$ 2,400,000

Conversion price per share

$ 0.2475

Lowest trade price

85.00%

July 2019 Debentures [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Principal amount

$ 154,000

Finance cost

$ 154,000

Securities Purchase Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Cash received

500,000

Cancellation amount

15,000

Debt conversion amount

$ 515,000

Exchange Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Remaining debt outstanding

$ 110,072

Principal amount

$ 320,000

Cash received

250,000

Cancellation amount

$ 70,000

$ 70,000

Debt conversion amount

$ 589,334

$ 1,310,068

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Aug. 15, 2015	Dec. 31, 2021	Sep. 30, 2021
Related Party Transaction [Line Items]
Convertible debentures		$ 290,000
Silvestre Law Group P C [Member]
Related Party Transaction [Line Items]
Payment to related parties			$ 10,000
Legal fees	$ 84,224	54,141
Payment for monthly fee		40,000
Amount due to related party		$ 294,005

LICENSE TERMINATION COST (Detai

LICENSE TERMINATION COST (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)shares
License Termination Cost
Termination of license agreement, description	the Company issued to Ridgeway 866,667 shares of common stock and 8,000 shares of Series F 0% Convertible Preferred Stock. Additionally, the Company paid approximately $25,000 of Ridgeway’s expenses and costs.
Common stock shares issued, shares | shares	866,667
Common stock shares issued, value	$ 266,500
license termination cost	$ 1,677,901

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryover	$ 9,343	$ 9,064
Stock-based compensation	1,920	1,920
Accrued compensation	334	334
Other	30	30
Tax credits	485	458
Total deferred tax assets	12,112	11,806
Less: valuation allowance	(12,112)	(11,806)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21.00%	21.00%
State income taxes, net of federal benefit	7.00%	7.00%
Non-deductible items	38.30%	24.40%
Valuation allowance	10.30%	3.60%
Effective income tax rate	0.00%	0.00%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 43,000,000
Net operating loss carryforwards expire amount	$ 39,900,000
Expiration period	expire at various dates through 2037.
Research and development tax credits	$ 485,000
Expiration period for tax credit	expire from 2028 through 2041.
Increased in valuation allowance	$ 306,000	$ 226,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Debentures converted to common stock	$ 2,694,000	$ 1,310,000
Senior Convertible debentures [Member]
Short-term Debt [Line Items]
Debentures converted to common stock	$ 461,972
Number of common shares issued upon conversion of debentures	20,363,686